Targeting PD-1 in cancer: Biological insights with a focus on breast cancer

被引：17

作者：

Solinas, Cinzia ^{[1
,2
]}

Aiello, Marco ^{[3
]}

De Silva, Pushpamali ^{[2
,4
]}

Gu-Trantien, Chunyan ^{[2
,5
]}

Migliori, Edoardo ^{[2
,6
]}

Willard-Gallo, Karen ^{[2
]}

机构：

[1] Reg Hosp Aosta, Azienda AUSL, Aosta, Italy

[2] Inst Jules Bordet, Mol Immunol Unit, Brussels, Belgium

[3] Azienda Osped Univ Policlin Vittorio Emanuele, Med Oncol Unit, Catania, Italy

[4] Univ Libre Bruxelles, Inst Jules Bordet, Clin & Expt Hematol, Brussels, Belgium

[5] Univ Libre Bruxelles, Inst Med Immunol, Brussels, Belgium

[6] Columbia Univ, Med Ctr, Columbia Ctr Translat Immunol, Black Bldg 650,West 168th St, New York, NY 10032 USA

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2019年 / 142卷

关键词：

PD-1/PD-Ls; Immunotherapy; Tumor microenvironment; Self-tolerance; T-CELL EXHAUSTION; PROGRAMMED DEATH-1 LIGAND-1; CLINICAL-SIGNIFICANCE; UP-REGULATION; EXPRESSION; BLOCKADE; PATHWAY; CARCINOMA; NIVOLUMAB; MELANOMA;

D O I：

10.1016/j.critrevonc.2019.07.011

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Programmed cell death-1 (PD-1) receptor and its ligands physiologically regulate the activity of the adaptive immune system to limit excessive inflammatory processes, thus preventing normal tissue damage. Tumor cells escape from the host immune surveillance using this pathway, rendering it relevant therapeutic target. Despite the relevant clinical efficacy observed in patients with solid and hematological malignancies, the clinical benefit of these novel treatments is limited to a relatively restricted number of patients. A wide amount of genomic and immune related features is currently under investigation as potential predictive biomarkers for treatment selection. The results obtained so far are encouraging but still imperfect. Combination strategies using different immunotherapeutic agents or with other treatments (such as chemotherapy) are being investigated, showing promising but still not completely satisfactory results. This review aims to shed light on the main principles of targeting PD-1 in breast cancer, from biology through its functional and clinical implications.

引用

页码：35 / 43

页数：9

共 104 条

[1] Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired [J].

Ahmadzadeh, Mojgan ;

Johnson, Laura A. ;

Heemskerk, Bianca ;

Wunderlich, John R. ;

Dudley, Mark E. ;

White, Donald E. ;

Rosenberg, Steven A. .

BLOOD, 2009, 114 (08) :1537-1544

[2] Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression [J].

Asano, Yuka ;

Kashiwagi, Shinichiro ;

Goto, Wataru ;

Takada, Koji ;

Takahashi, Katsuyuki ;

Morisaki, Tamami ;

Fujita, Hisakazu ;

Takashima, Tsutomu ;

Tomita, Shuhei ;

Ohsawa, Masahiko ;

Hirakawa, Kosei ;

Ohira, Masaichi .

JOURNAL OF TRANSLATIONAL MEDICINE, 2018, 16

[3] The PD1:PD-L1/2 Pathway from Discovery to Clinical implementation [J].

Bardhan, Kankana ;

Anagnostou, Theodora ;

Boussiotis, Vassiliki A. .

FRONTIERS IN IMMUNOLOGY, 2016, 7

[4] The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers [J].

Barrett, Michael T. ;

Lenkiewicz, Elizabeth ;

Malasi, Smriti ;

Basu, Anamika ;

Yearley, Jennifer Holmes ;

Annamalai, Lakshmanan ;

McCullough, Ann E. ;

Kosiorek, Heidi E. ;

Narang, Pooja ;

Sayres, Melissa A. Wilson ;

Chen, Meixuan ;

Anderson, Karen S. ;

Pockaj, Barbara A. .

BREAST CANCER RESEARCH, 2018, 20

[5] Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection [J].

Blackburn, Shawn D. ;

Shin, Haina ;

Haining, W. Nicholas ;

Zou, Tao ;

Workman, Creg J. ;

Polley, Antonio ;

Betts, Michael R. ;

Freeman, Gordon J. ;

Vignali, Dario A. A. ;

Wherry, E. John .

NATURE IMMUNOLOGY, 2009, 10 (01) :29-37

[6] Impact of Epitope Escape on PD-1 Expression and CD8 T-Cell Exhaustion during Chronic Infection [J].

Blattman, Joseph N. ;

Wherry, E. John ;

Ha, Sang-Jun ;

van der Most, Robbert G. ;

Ahmed, Rafi .

JOURNAL OF VIROLOGY, 2009, 83 (09) :4386-4394

[7] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[8]

Brockhoff Gero, 2018, Oncotarget, V9, P6201, DOI 10.18632/oncotarget.23717

[9] T-bet and Eomes Are Differentially Linked to the Exhausted Phenotype of CD8+T Cells in HIV Infection [J].

Buggert, Marcus ;

Tauriainen, Johanna ;

Yamamoto, Takuya ;

Frederiksen, Juliet ;

Ivarsson, Martin A. ;

Michaelsson, Jakob ;

Lund, Ole ;

Hejdeman, Bo ;

Jansson, Marianne ;

Sonnerborg, Anders ;

Koup, Richard A. ;

Betts, Michael R. ;

Karlsson, Annika C. .

PLOS PATHOGENS, 2014, 10 (07)

[10] Tumor-infiltrating lymphocyte composition, organization and PD-1/PD-L1 expression are linked in breast cancer [J].

Buisseret, Laurence ;

Garaud, Soizic ;

de Wind, Alexandre ;

Van den Eynden, Gert ;

Boisson, Anais ;

Solinas, Cinzia ;

Gu-Trantien, Chunyan ;

Naveaux, Celine ;

Lodewyckx, Jean-Nicolas ;

Duvillier, Hugues ;

Craciun, Ligia ;

Veys, Isabelle ;

Larsimont, Denis ;

Piccart-Gebhart, Martine ;

Stagg, John ;

Sotiriou, Christos ;

Willard-Gallo, Karen .

ONCOIMMUNOLOGY, 2017, 6 (01)

← 1 2 3 4 5 6 7 8 9 10 →